Drug Price Transparency in Medicaid Act of 2023

Drug Price Transparency in Medicaid Act of 2023

This bill requires pass-through pricing models, and prohibits spread-pricing, for payment arrangements with pharmacy benefit managers under Medicaid. The bill also extends funding for retail pharmacy surveys and requires additional information with respect to price concessions and survey participation to be made publicly available.

Bill 118 HR 1613, also known as the Drug Price Transparency in Medicaid Act of 2023, aims to increase transparency in drug pricing within the Medicaid program. The bill requires drug manufacturers to provide detailed information on the pricing of their drugs to the Centers for Medicare and Medicaid Services (CMS). This information includes the production costs, research and development expenses, and any discounts or rebates offered.

The bill also requires CMS to publish this information on a publicly accessible website, allowing patients, healthcare providers, and policymakers to better understand the factors influencing drug prices. Additionally, the bill mandates that drug manufacturers notify CMS of any price increases above a certain threshold, ensuring that any sudden spikes in drug prices are closely monitored.

Furthermore, the Drug Price Transparency in Medicaid Act of 2023 includes provisions to address price gouging and anti-competitive practices in the pharmaceutical industry. It empowers CMS to take action against drug manufacturers engaging in unfair pricing practices, such as unjustified price increases or price discrimination. Overall, this bill seeks to promote transparency and accountability in drug pricing within the Medicaid program, ultimately aiming to lower drug costs for patients and improve access to affordable medications.